Rigel Pharmaceuticals (RIGL) Shares Outstanding (Diluted Average) (2010 - 2026)
Rigel Pharmaceuticals' quarterly Shares Outstanding (Diluted Average) came in at $19.7 million in Q1 2026, up 8.35% year-on-year from $18.2 million in Q1 2025, and up 4.49% quarter-over-quarter from $18.8 million in Q4 2025.
Rigel Pharmaceuticals has reported Shares Outstanding (Diluted Average) for 11 years, with the latest figure at $19.7 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 8.35% year-over-year to $19.7 million; the trailing twelve-month figure through Mar 2026 stood at $19.7 million (up 8.35% YoY), and the FY2025 full-year result was $18.8 million, up 6.52% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $19.7 million, up from $18.8 million in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $173.6 million in Q1 2023, with the low at $17.0 million in Q4 2022.
- Average Shares Outstanding (Diluted Average) over 5 years is $54.3 million, with a median of $18.2 million recorded in 2025.
- Year-over-year, Shares Outstanding (Diluted Average) plunged 90.0% in 2022 and grew 8.35% in 2026.
- Tracing RIGL's Shares Outstanding (Diluted Average) over 5 years: stood at $17.0 million in 2022, then increased by 2.06% to $17.4 million in 2023, then gained by 1.64% to $17.7 million in 2024, then grew by 6.52% to $18.8 million in 2025, then gained by 4.49% to $19.7 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $19.7 million (Q1 2026), $18.8 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 19.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.69 Mn |
| Dec 31, 2025 | 18.84 Mn |
| Sep 30, 2025 | 18.38 Mn |
| Jun 30, 2025 | 18.16 Mn |
| Mar 31, 2025 | 18.17 Mn |
| Dec 31, 2024 | 17.69 Mn |
| Sep 30, 2024 | 17.65 Mn |
| Jun 30, 2024 | 17.55 Mn |
| Mar 31, 2024 | 17.52 Mn |
| Dec 31, 2023 | 17.40 Mn |
| Sep 30, 2023 | 17.39 Mn |
| Jun 30, 2023 | 17.36 Mn |
| Mar 31, 2023 | 173.57 Mn |
| Dec 31, 2022 | 17.05 Mn |
| Sep 30, 2022 | 172.84 Mn |
| Jun 30, 2022 | 172.15 Mn |
| Mar 31, 2022 | 171.77 Mn |
| Dec 31, 2021 | 170.49 Mn |
| Sep 30, 2021 | 176.45 Mn |
| Jun 30, 2021 | 175.91 Mn |
| Mar 31, 2021 | 176.07 Mn |
| Dec 31, 2020 | 168.75 Mn |
| Sep 30, 2020 | 168.66 Mn |
| Jun 30, 2020 | 168.53 Mn |
| Mar 31, 2020 | 168.57 Mn |
| Dec 31, 2019 | 167.40 Mn |
| Jun 30, 2019 | 167.18 Mn |
| Mar 31, 2019 | 167.17 Mn |
| Sep 30, 2012 | 71.64 Mn |
| Jun 30, 2012 | 71.46 Mn |
| Mar 31, 2012 | 71.42 Mn |
| Dec 31, 2011 | 63.33 Mn |
| Sep 30, 2011 | 71.23 Mn |
| Jun 30, 2011 | 58.27 Mn |
| Mar 31, 2011 | 52.28 Mn |
| Dec 31, 2010 | 52.57 Mn |
| Sep 30, 2010 | 52.77 Mn |
| Jun 30, 2010 | 52.48 Mn |